New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome
| Autor: | E. V. Morozova, N. Yu. Tsvetkov, M. V. Barabanshchikova, K. S. Yurovskaya, I. S. Moiseev |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Онкогематология, Vol 17, Iss 4, Pp 106-117 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1818-8346 2413-4023 |
| DOI: | 10.17650/1818-8346-2022-17-4-106-117 |
| Popis: | Currently, therapeutic tactics in patients with myelodysplastic syndrome is based on risk-adapted therapy followed by allogeneic hematopoietic stem cell transplantation, which remains the only radical method of treatment. for patients who cannot undergo transplantation, the problem of finding new methods of treatment remains urgent. Modern knowledge about the pathogenesis of the disease allows us to get an idea of the key pathways associated with oncogenesis and to develop new epigenetic methods of treatment.Aim. To consider the therapeutic approaches currently used in the treatment of patients with myelodysplastic syndrome of low and high risk groups, as well as to demonstrate the relevance of the search for new methods of targeted and immunotherapy. In this review, we highlight the achievements in the field of targeted therapy, in particular, the study of the biology of the TIM3 molecule and its ligands, new data from clinical trials of anti-TIM3 monoclonal antibodies. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|